Dr. Petrylak Discusses BCG for the Treatment of Patients With Non-Invasive Bladder Cancer
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.
BCG is a standard treatment for superficial bladder cancer, and it delays progression; and in certain studies, it shows an improvement in overall survival, says Petrylak. Unfortunately, there are not many therapeutic options available once patients fail BCG. The standard treatment is cystectomy, but the main goal for Petrylak and his colleagues is to have patients that are cancer free with their bladder intact.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
